JPWO2019105435A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2019105435A5
JPWO2019105435A5 JP2020529638A JP2020529638A JPWO2019105435A5 JP WO2019105435 A5 JPWO2019105435 A5 JP WO2019105435A5 JP 2020529638 A JP2020529638 A JP 2020529638A JP 2020529638 A JP2020529638 A JP 2020529638A JP WO2019105435 A5 JPWO2019105435 A5 JP WO2019105435A5
Authority
JP
Japan
Prior art keywords
nucleotide
group
sirna
seq
nucleotide sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020529638A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021503941A (ja
JP2021503941A5 (hu
JP7273417B2 (ja
Publication date
Application filed filed Critical
Priority claimed from PCT/CN2018/118300 external-priority patent/WO2019105435A1/zh
Publication of JP2021503941A publication Critical patent/JP2021503941A/ja
Publication of JP2021503941A5 publication Critical patent/JP2021503941A5/ja
Publication of JPWO2019105435A5 publication Critical patent/JPWO2019105435A5/ja
Application granted granted Critical
Publication of JP7273417B2 publication Critical patent/JP7273417B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020529638A 2017-12-01 2018-11-29 核酸、当該核酸を含む組成物および複合体ならびに調製方法と使用 Active JP7273417B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN201711249378.5 2017-12-01
CN201711249378 2017-12-01
CN201711478933.1 2017-12-29
CN201711478933 2017-12-29
PCT/CN2018/118300 WO2019105435A1 (zh) 2017-12-01 2018-11-29 一种核酸、含有该核酸的组合物与缀合物及制备方法和用途

Publications (4)

Publication Number Publication Date
JP2021503941A JP2021503941A (ja) 2021-02-15
JP2021503941A5 JP2021503941A5 (hu) 2022-01-06
JPWO2019105435A5 true JPWO2019105435A5 (hu) 2022-09-22
JP7273417B2 JP7273417B2 (ja) 2023-05-15

Family

ID=66664718

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020529638A Active JP7273417B2 (ja) 2017-12-01 2018-11-29 核酸、当該核酸を含む組成物および複合体ならびに調製方法と使用

Country Status (6)

Country Link
US (2) US11414665B2 (hu)
EP (1) EP3718572A4 (hu)
JP (1) JP7273417B2 (hu)
CN (1) CN110944675B (hu)
TW (1) TW201925468A (hu)
WO (1) WO2019105435A1 (hu)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019105419A1 (zh) 2017-12-01 2019-06-06 苏州瑞博生物技术有限公司 一种核酸、含有该核酸的组合物与缀合物及制备方法和用途
CA3083968C (en) 2017-12-01 2024-04-23 Suzhou Ribo Life Science Co., Ltd. Double-stranded oligonucleotide, composition and conjugate comprising double-stranded oligonucleotide, preparation method thereof and use thereof
US11633482B2 (en) 2017-12-29 2023-04-25 Suzhou Ribo Life Science Co., Ltd. Conjugates and preparation and use thereof
WO2020038377A1 (zh) 2018-08-21 2020-02-27 苏州瑞博生物技术有限公司 一种核酸、含有该核酸的药物组合物和缀合物及其用途
JP7376952B2 (ja) 2018-09-30 2023-11-09 スーチョウ リボ ライフ サイエンス カンパニー、リミテッド ｓｉＲＮＡ複合体及びその調製方法と使用
US20220186221A1 (en) * 2019-05-24 2022-06-16 Suzhou Ribo Life Science Co., Ltd. Nucleic acid, pharmaceutical composition and conjugate, preparation method and use
CN114634929A (zh) * 2020-12-16 2022-06-17 施能康生物科技有限公司 靶向前蛋白转化酶枯草杆菌转化酶的核酸及其用途
WO2022206946A1 (zh) * 2021-04-02 2022-10-06 上海拓界生物医药科技有限公司 乙型肝炎病毒siRNA和siRNA缀合物
WO2023284763A1 (zh) * 2021-07-16 2023-01-19 苏州瑞博生物技术股份有限公司 双链寡核苷酸、含双链寡核苷酸的组合物与缀合物及制备方法和用途
WO2023116764A1 (zh) * 2021-12-23 2023-06-29 苏州瑞博生物技术股份有限公司 一种核酸、含有该核酸的组合物与缀合物及其用途
CN117396537A (zh) * 2022-04-12 2024-01-12 厦门赛诺邦格生物科技股份有限公司 一种非线性聚乙二醇化脂质及其应用

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030206887A1 (en) * 1992-05-14 2003-11-06 David Morrissey RNA interference mediated inhibition of hepatitis B virus (HBV) using short interfering nucleic acid (siNA)
CN1257284C (zh) * 2003-03-05 2006-05-24 北京博奥生物芯片有限责任公司 一种体外阻断乙肝病毒表达的方法
ES2702942T3 (es) 2003-04-17 2019-03-06 Alnylam Pharmaceuticals Inc Agentes de ARNi modificados
EP1752536A4 (en) * 2004-05-11 2008-04-16 Alphagen Co Ltd POLYNUCLEOTIDE CAUSING RNA INTERFERENCE AND METHOD OF REGULATING GENE EXPRESSION WITH THE USE OF THE SAME
EP1791567B1 (en) 2004-08-10 2015-07-29 Alnylam Pharmaceuticals Inc. Chemically modified oligonucleotides
KR20100060018A (ko) 2005-03-09 2010-06-04 재단법인 목암생명공학연구소 작은 간섭 ｒｎａ 및 이를 포함하는 ｂ형 간염 바이러스 치료용 약학 조성물
AU2014208251B2 (en) 2007-12-04 2016-07-14 Alnylam Pharmaceuticals, Inc. Carbohydrate conjugates as delivery agents for oligonucleotides
CA2910760C (en) 2007-12-04 2019-07-09 Muthiah Manoharan Targeting lipids
CN101603042B (zh) * 2008-06-13 2013-05-01 厦门大学 可用于乙型肝炎病毒感染治疗的rna干扰靶点
CN102083983B (zh) 2008-08-01 2014-04-16 苏州瑞博生物技术有限公司 乙型肝炎病毒基因的小核酸干扰靶位点序列和小干扰核酸及组合物和应用
CA2750561C (en) * 2009-01-26 2017-10-10 Protiva Biotherapeutics, Inc. Compositions and methods for silencing apolipoprotein c-iii expression
US8975389B2 (en) 2009-03-02 2015-03-10 Alnylam Pharmaceuticals, Inc. Nucleic acid chemical modifications
NZ597504A (en) 2009-06-15 2013-10-25 Alnylam Pharmaceuticals Inc Lipid formulated dsrna targeting the pcsk9 gene
CN102140461B (zh) 2010-01-29 2012-12-05 苏州瑞博生物技术有限公司 小干扰核酸和药物组合物及其制药应用
CN102140458B (zh) 2010-01-29 2013-05-22 苏州瑞博生物技术有限公司 小干扰核酸和药物组合物及其制药应用
EP2601204B1 (en) 2010-04-28 2016-09-07 Ionis Pharmaceuticals, Inc. Modified nucleosides and oligomeric compounds prepared therefrom
CN102344477B (zh) * 2010-07-27 2015-04-08 苏州瑞博生物技术有限公司 一种核苷酸和/或寡核苷酸及其制备方法
CA2807307C (en) * 2010-08-17 2021-02-09 Merck Sharp & Dohme Corp. Rna interference mediated inhibition of hepatitis b virus (hbv) gene expression using short interfering nucleic acid (sina)
US9290760B2 (en) 2010-09-15 2016-03-22 Alnylam Pharmaceuticals, Inc. Modified iRNA agents
CN103380113B (zh) 2010-11-15 2018-03-30 生命科技公司 含胺的转染试剂及其制备和使用方法
US8501930B2 (en) 2010-12-17 2013-08-06 Arrowhead Madison Inc. Peptide-based in vivo siRNA delivery system
KR102481317B1 (ko) 2011-03-29 2022-12-26 알닐람 파마슈티칼스 인코포레이티드 Tmprss6 유전자의 발현을 억제하기 위한 조성물 및 방법
ES2923573T3 (es) * 2011-06-21 2022-09-28 Alnylam Pharmaceuticals Inc Composiciones de ARNi de proteína 3 de tipo angiopoyetina (ANGPTL3) y métodos de uso de las mismas
MX342731B (es) 2011-06-30 2016-10-11 Arrowhead Res Corp Composiciones y metodos para inhibir la expresion genica del virus de hepatitis b.
KR102272498B1 (ko) 2011-10-27 2021-07-06 메사추세츠 인스티튜트 오브 테크놀로지 약물 캡슐화 마이크로스피어를 형성할 수 있는, ｎ-말단 상에 관능화된 아미노산 유도체
CN104717982B (zh) 2012-08-06 2018-08-28 阿尔尼拉姆医药品有限公司 碳水化合物共轭物及其制备改进工艺
FR2998748B1 (fr) 2012-11-23 2015-04-10 Commissariat Energie Atomique Dispositif et procede de retransmission de donnees dans un commutateur reseau
HUE035887T2 (hu) 2012-12-05 2018-05-28 Alnylam Pharmaceuticals Inc PCSK9 iRNS készítmények és eljárások azok alkalmazására
SI2970974T1 (sl) 2013-03-14 2017-12-29 Alnylam Pharmaceuticals, Inc. Komplementarna komponenta C5 sestavkov IRNA in postopki njene uporabe
EP2992009B1 (en) 2013-05-01 2020-06-24 Ionis Pharmaceuticals, Inc. Compositions and methods for modulating apolipoprotein (a) expression
US10246708B2 (en) 2013-05-06 2019-04-02 Alnylam Pharmaceuticals, Inc. Dosages and methods for delivering lipid formulated nucleic acid molecules
CN104107437B (zh) * 2013-06-09 2015-08-26 厦门成坤生物技术有限公司 一种用于治疗乙型病毒性肝炎的rna干扰组合物及其制备方法
AU2014287002A1 (en) * 2013-07-11 2016-02-11 Alnylam Pharmaceuticals, Inc. Oligonucleotide-ligand conjugates and process for their preparation
EP3137091B1 (en) 2014-05-01 2020-12-02 Ionis Pharmaceuticals, Inc. Conjugates of modified antisense oligonucleotides and their use for modulating pkk expression
US20170114341A1 (en) 2014-06-06 2017-04-27 Solstice Biologics, Ltd. Polynucleotide constructs having bioreversible and non-bioreversible groups
SG10201913791QA (en) * 2014-08-20 2020-03-30 Alnylam Pharmaceuticals Inc Modified double-stranded rna agents
JOP20200092A1 (ar) 2014-11-10 2017-06-16 Alnylam Pharmaceuticals Inc تركيبات iRNA لفيروس الكبد B (HBV) وطرق لاستخدامها
EP3221451A1 (en) * 2014-11-17 2017-09-27 Alnylam Pharmaceuticals, Inc. Apolipoprotein c3 (apoc3) irna compositions and methods of use thereof
JP2018509913A (ja) 2015-03-17 2018-04-12 アローヘッド ファーマシューティカルズ インコーポレイテッド 第ｘｉｉ因子の遺伝子発現を阻害するための組成物と方法
CN115927335A (zh) 2015-04-13 2023-04-07 阿尔尼拉姆医药品有限公司 类血管生成素3（ANGPTL3）iRNA组合物及其使用方法
WO2016179342A2 (en) 2015-05-06 2016-11-10 Alnylam Pharmaceuticals, Inc. Factor xii (hageman factor) (f12), kallikrein b, plasma (fletcher factor) 1 (klkb1), and kininogen 1 (kng1) irna compositions and methods of use thereof
JP6715325B2 (ja) 2015-06-26 2020-07-01 スーチョウ リボ ライフ サイエンス カンパニー、リミテッドＳｕｚｈｏｕ Ｒｉｂｏ Ｌｉｆｅ Ｓｃｉｅｎｃｅ Ｃｏ．， Ｌｔｄ． ｓｉＲＮＡ、ｓｉＲＮＡを含む医薬組成物及び結合体、並びにそれらの応用
AU2016296592B2 (en) * 2015-07-17 2021-08-19 Arcturus Therapeutics, Inc. Compositions and agents against Hepatitis B virus and uses thereof
US20180216114A1 (en) 2015-07-27 2018-08-02 Alnylam Pharmaceuticals, Inc. Xanthine dehydrogenase (xdh) irna compositions and methods of use thereof
KR20180038465A (ko) 2015-08-07 2018-04-16 애로우헤드 파마슈티컬스 인코포레이티드 Ｂ형 간염 바이러스 감염에 대한 ｒｎａｉ 치료법
CN114939124A (zh) 2015-08-25 2022-08-26 阿尔尼拉姆医药品有限公司 治疗前蛋白转化酶枯草杆菌蛋白酶kexin(pcsk9)基因相关障碍的方法和组合物
US10883107B2 (en) 2016-01-08 2021-01-05 Alnylam Pharmaceuticals, Inc. Polynucleotide agents targeting factor XII (hageman factor) (F12) and methods of use thereof
JOP20170161A1 (ar) 2016-08-04 2019-01-30 Arrowhead Pharmaceuticals Inc عوامل RNAi للعدوى بفيروس التهاب الكبد ب
EP3500581A4 (en) 2016-08-17 2021-10-06 Solstice Biologics, Ltd. POLYNUCLEOTIDE CONSTRUCTS
CA3048661A1 (en) 2017-01-30 2018-08-02 Arrowhead Pharmaceuticals Inc. Compositions and methods for inhibition of factor xii gene expression
JP2022506517A (ja) 2018-11-02 2022-01-17 アルブータス・バイオファーマー・コーポレイション 標的指向化二価結合体

Similar Documents

Publication Publication Date Title
JP2021503941A5 (hu)
JP2021503929A5 (hu)
JP2021503930A5 (hu)
JP2021503940A5 (hu)
CN109562188B (zh) 与三价糖缀合物连接的核酸
US8168605B2 (en) Polymeric oligonucleotide prodrugs
JPWO2019105435A5 (hu)
JP2019513771A (ja) トリチル−モノ−ＧａｌＮＡｃ化合物とその利用
JPWO2019105414A5 (hu)
JPWO2019092283A5 (hu)
JP2010538677A5 (hu)
CN112424352A (zh) 包括7′-5′-α-异头双环糖核苷的寡核苷酸缀合物
US20210179658A1 (en) Orthogonal protecting groups for the preparation of stereodefined phosphorothioate oligonucleotides
AU2017326372A1 (en) Modified oligonucleotides and methods of use
TW202220695A (zh) 寡核苷酸之全身遞送
CN111228288A (zh) 寡核苷酸组合物及其制备方法
JPWO2020063198A5 (hu)
US20040033967A1 (en) Alkylated hexitol nucleoside analogues and oligomers thereof
JPWO2021178885A5 (hu)
JPWO2021049504A5 (hu)
JPWO2020233655A5 (hu)
JPWO2020238766A5 (hu)
JPWO2020233650A5 (hu)
JPWO2020238758A5 (hu)
JPWO2020038377A5 (hu)